Department of Neurology, Fukuoka University Fukuoka, Japan.
Expert Opin Drug Saf. 2022 Feb;21(2):137-147. doi: 10.1080/14740338.2022.1988926. Epub 2021 Oct 15.
While levodopa is still the most effective treatment for Parkinson's disease, concerns about long-term complications such as wearing-off and dyskinesia with levodopa usage remain.
Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. This review outlines the pharmacological properties, therapeutic effects, and tolerability of safinamide as an adjunct to levodopa in patients with advanced PD. Efficacy and safety findings from double-blind and placebo-controlled clinical trials for safinamide as an adjunct therapy to levodopa for PD are summarized.
Safinamide was well tolerated as a treatment for PD, and there was no significant difference in the frequency and severity of adverse events between the safinamide and placebo groups. It was also suggested that safinamide had a beneficial effect on the accompanying non-motor symptoms such as PD-related pain. Safinamide may exhibit neuroprotective effects through antioxidant and anti-glutamate effects, and research on the disease-modifying effect of PD is desired in the future.
虽然左旋多巴仍然是治疗帕金森病最有效的方法，但长期使用左旋多巴所带来的副作用，如药效减退和运动障碍等问题仍然令人担忧。
沙芬酰胺是一种高选择性和可逆的单胺氧化酶 B 抑制剂，在欧盟、日本和美国被批准为左旋多巴的辅助药物，用于治疗伴有运动波动的帕金森病患者。本综述概述了沙芬酰胺作为左旋多巴辅助治疗药物在晚期帕金森病患者中的药理学特性、治疗效果和耐受性。总结了沙芬酰胺作为左旋多巴辅助治疗药物治疗帕金森病的双盲和安慰剂对照临床试验的疗效和安全性发现。
沙芬酰胺作为帕金森病的治疗药物具有良好的耐受性，沙芬酰胺组和安慰剂组不良反应的频率和严重程度没有显著差异。沙芬酰胺对帕金森病相关疼痛等伴随的非运动症状也有有益的影响。沙芬酰胺可能通过抗氧化和抗谷氨酸作用发挥神经保护作用，未来需要研究其对帕金森病的疾病修饰作用。
